drugset / Trial / NCT01889095

Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients

NCT01889095

Phase 4 Completed 160 enrolled Tehran University of Medical Sciences
RandomizedParallel-groupSingle-blindTreatment

Summary

Glycemic control is fundamental in the management of diabetes mellitus .If lifestyle intervention and full tolerated doses of one or two oral glucose lowering drugs (OGLDs) fail to achieve or sustain glycemic goals, insulin should be initiated. New insulin analogs are generated to improve glycemic control .New insulin analogs are generated to improve glycemic control,However, the cost of these analogs is a major problem .The aim of this piggy back evaluation was to assess the effect of BIAsp 30 versus NPH plus regular human insulin on metabolic control as well as its cost-effectiveness in people with type 2 diabetes in the Iranian setting.

Timeline

Start
2011-07
Primary completion
2011-08
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BIAsp 30 Unknown 0.2 iu/kg
Subject BIAsp 30 Unknown 0.6 iu/kg
Comparator NPH/Reg Unknown 0.2 iu/kg
Comparator NPH/Reg Unknown 0.6 iu/kg